Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
NextCure ( (NXTC) ) has provided an announcement.
NextCure, Inc. is making strides in the financial markets with its new Investigational New Drug Application for LNCB74, targeting breast, endometrial, and ovarian cancers. This innovative antibody-drug conjugate employs a unique glucuronidase linker for enhanced safety and efficacy. With promising preclinical results and a strategic collaboration with LegoChemBio, the company is poised to initiate Phase 1 trials in early 2025, potentially offering a significant investment opportunity for those interested in groundbreaking cancer therapies.
For an in-depth examination of NXTC stock, go to TipRanks’ Stock Analysis page.
